Robert Arthur Kyle, MD: a conversation with the editor.
作者信息
Kyle Robert Arthur, Roberts William Clifford
机构信息
Departments of Medicine and Laboratory Medicine and Pathology, College of Medicine, Mayo Clinic, Rochester, Minnesota (Kyle), and the Baylor Heart and Vascular Institute, Baylor University Medical Center at Dallas (Roberts).
出版信息
Proc (Bayl Univ Med Cent). 2010 Oct;23(4):400-18. doi: 10.1080/08998280.2010.11928660.
Abstract
摘要
相似文献
1
Robert Arthur Kyle, MD: a conversation with the editor.医学博士罗伯特·亚瑟·凯尔：与编辑的对话
Proc (Bayl Univ Med Cent). 2010 Oct;23(4):400-18. doi: 10.1080/08998280.2010.11928660.
2
Arthur Garson, Jr., MD, MPH: a conversation with the editor. Interview by William Clifford Roberts.小亚瑟·加森医学博士、公共卫生硕士：与编辑的对话。威廉·克利福德·罗伯茨访谈
Am J Cardiol. 2003 Aug 15;92(4):421-35. doi: 10.1016/s0002-9149(03)00703-3.
3
Denton Arthur Cooley, MD: a conversation with the editor. Interview by William Clifford Roberts.医学博士丹顿·亚瑟·库利：与编辑的对话。威廉·克利福德·罗伯茨访谈
Am J Cardiol. 1997 Apr 15;79(8):1078-91. doi: 10.1016/s0002-9149(97)00035-0.
4
Robert Gary Mennel, MD: a conversation with the editor.医学博士罗伯特·加里·门内尔：与编辑的对话
Proc (Bayl Univ Med Cent). 2006 Oct;19(4):374-85. doi: 10.1080/08998280.2006.11928202.
5
Robert Lee Fine, MD: a conversation with the editor. Interview by William Clifford Roberts.医学博士罗伯特·李·法恩：与编辑的对话。威廉·克利福德·罗伯茨访谈。
Proc (Bayl Univ Med Cent). 2005 Oct;18(4):379-93. doi: 10.1080/08998280.2005.11928098.
6
Henry Arthur Solomon, MD: a conversation with the editor. Interview by Roberts WC.医学博士亨利·亚瑟·所罗门：与编辑的对话。由罗伯茨·WC进行访谈。
Am J Cardiol. 2000 Jul 15;86(2):198-204. doi: 10.1016/s0002-9149(00)00941-3.
7
Robert Pickett Scruggs III, MD: a conversation with the editor. Interview by William Clifford Roberts.医学博士罗伯特·皮克特·斯克鲁格斯三世：与编辑的对话。威廉·克利福德·罗伯茨访谈。
Proc (Bayl Univ Med Cent). 2002 Oct;15(4):391-402. doi: 10.1080/08998280.2002.11927872.
8
Robert Ogden Bonow, MD: a conversation with the editor. Interview by William Clifford Roberts.医学博士罗伯特·奥格登·博诺：与编辑的对话。威廉·克利福德·罗伯茨访谈。
Am J Cardiol. 1998 Jun 15;81(12):1474-88. doi: 10.1016/s0002-9149(98)00282-3.
9
Robert McKinnon Califf, MD: a conversation with the editor. Interview by William Clifford Roberts.医学博士罗伯特·麦金农·卡利夫：与编辑的对话。威廉·克利福德·罗伯茨访谈。
Am J Cardiol. 1998 Sep 1;82(5):639-58. doi: 10.1016/s0002-9149(98)00482-2.
10
Robert Wilson Jackson, OC, MD, FRCS, FRCSC, FRCS(Ed): a conversation with the editor. Interview by William Clifford Roberts.罗伯特·威尔逊·杰克逊，加拿大勋章获得者，医学博士，英国皇家外科医学院院士，加拿大皇家外科医学院院士，爱丁堡皇家外科医学院院士：与编辑的对话。威廉·克利福德·罗伯茨采访。
Proc (Bayl Univ Med Cent). 2002 Apr;15(2):171-84. doi: 10.1080/08998280.2002.11927835.
本文引用的文献
1
Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study.意义未明单克隆免疫球蛋白血症轻链型的流行率和进展风险：一项回顾性基于人群的队列研究。
Lancet. 2010 May 15;375(9727):1721-8. doi: 10.1016/S0140-6736(10)60482-5.
2
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management.意义未明的单克隆丙种球蛋白血症（MGUS）和冒烟型（无症状）多发性骨髓瘤：IMWG 共识观点——进展风险因素以及监测和管理指南。
Leukemia. 2010 Jun;24(6):1121-7. doi: 10.1038/leu.2010.60. Epub 2010 Apr 22.
3
Treatment of multiple myeloma: a comprehensive review.多发性骨髓瘤的治疗：全面综述
Clin Lymphoma Myeloma. 2009 Aug;9(4):278-88. doi: 10.3816/CLM.2009.n.056.
4
Disease associations with monoclonal gammopathy of undetermined significance: a population-based study of 17,398 patients.意义未明的单克隆丙种球蛋白病与疾病的关联：一项基于17398例患者的人群研究。
Mayo Clin Proc. 2009 Aug;84(8):685-93. doi: 10.4065/84.8.685.
5
Pesticide exposure and risk of monoclonal gammopathy of undetermined significance in the Agricultural Health Study.农业健康研究中农药暴露与意义未明的单克隆丙种球蛋白病风险
Blood. 2009 Jun 18;113(25):6386-91. doi: 10.1182/blood-2009-02-203471. Epub 2009 Apr 22.
6
IgM monoclonal gammopathy of undetermined significance and smoldering Waldenström's macroglobulinemia.意义未明的IgM单克隆丙种球蛋白病和冒烟型华氏巨球蛋白血症。
Clin Lymphoma Myeloma. 2009 Mar;9(1):17-8. doi: 10.3816/CLM.2009.n.002.
7
The treatment of multiple myeloma using vincristine, carmustine, melphalan, cyclophosphamide, and prednisone (VBMCP) alternating with high-dose cyclophosphamide and alpha(2)beta interferon versus VBMCP: results of a phase III Eastern Cooperative Oncology Group Study E5A93.使用长春新碱、卡莫司汀、美法仑、环磷酰胺和泼尼松（VBMCP）交替联合大剂量环磷酰胺及α(2)β干扰素治疗多发性骨髓瘤与VBMCP治疗的比较：东部肿瘤协作组III期研究E5A93的结果
Cancer. 2009 May 15;115(10):2155-64. doi: 10.1002/cncr.24221.
8
Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance.多发性骨髓瘤或意义未明的单克隆丙种球蛋白病患者的一级亲属患单克隆丙种球蛋白病的风险增加。
Blood. 2009 Jul 23;114(4):785-90. doi: 10.1182/blood-2008-12-192575. Epub 2009 Jan 29.
9
Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study.意义未明的单克隆丙种球蛋白病（MGUS）始终先于多发性骨髓瘤：一项前瞻性研究。
Blood. 2009 May 28;113(22):5412-7. doi: 10.1182/blood-2008-12-194241. Epub 2009 Jan 29.
10
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders.国际骨髓瘤工作组关于多发性骨髓瘤及相关疾病血清游离轻链分析的指南。
Leukemia. 2009 Feb;23(2):215-24. doi: 10.1038/leu.2008.307. Epub 2008 Nov 20.
Zotero 插件